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A dearth of clinical research involving children has resulted in off license and 
sometimes inappropriate medications being prescribed to the paediatric 
population. In this environment, recent years have seen the introduction of a 
raft of regulation aimed at increasing the involvement of children in clinical 
trials research and generating evidenced based medicinal preparations for 
their use. However, this regulation pays scant attention to the autonomy of 
competent minors. In particular, it makes no provision for the ability of 
competent minors to consent to participate in medical research and is 
therefore at odds with best ethical practice. This article explores the tensions 
between law and ethics in relation to clinical research involving minors and 
concludes that greater respect should be given to the autonomy of those who 




In the past children have often been the victims of research 
abuses. 1  Their physical frailty, immaturity, and limited ability to 
exercise individual autonomy makes them especially vulnerable, 
particularly in their early years. Consequently, real concerns arise 
about exposing children to the risks associated with medical 
research, and this has resulted in a profound reluctance to conduct 
trials involving children.2 However, the historical failure to involve 
children in clinical research and trials of medicinal products means 
that many of the treatments prescribed to children are not 
supported by validated clinical evidence.3 Drugs designed for use 
in adults and not licensed for paediatric use are frequently 
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prescribed to children ‘off label’ for want of child specific 
preparations. This is despite the fact that children’s physiology is 
different to that of adults and alters with their physical 
development, which has sometimes led to the implementation of 
ineffective, or perhaps even harmful, treatment regimes.4   
 
The paucity of research involving children has occurred despite the 
fact that ethical guidelines have long recognised its importance. 
For example, in 1964 the World Health Organisation’s Declaration 
of Helsinki endorsed research in vulnerable populations, including 
children, if ‘the research is necessary to promote the health of the 
population represented and ... cannot instead be performed on 
legally competent persons’. Guidelines such as this have been 
highly influential in shaping the law and regulation that governs 
clinical research in the UK today.  For instance, the Helsinki 
principles are evident in the European Clinical Trials Directive 
2001/EC/20, which regulates clinical trials of investigational 
medicinal products and was transposed into UK law by the Clinical 
Trials Regulations 2004.5 The Directive also reflects, and explicitly 
acknowledges, increasing concerns about the failure to involve 
children in research,6 with Paragraph 3 of its preamble stating that: 
 
there is a need for clinical trials involving children to improve 
the treatment available to them. Children represent a 
vulnerable population with developmental, physiological and 
psychological differences from adults, which make age – and 
development - related research important for their benefit. 
 
With this in mind the European Regulation No 1901/2006 on 
medicinal products for paediatric use came into force in January 
2007.7  Its central aim is to ‘to improve the information available on 
the use of medicinal products in the various paediatric 
populations’,8 and it is designed to facilitate paediatric trials which 
seek to give children greater access to medicines that have been 
specifically designed or adapted and licensed for their use. Such 
trials must be performed in compliance with the European 
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Directive, and must not subject ‘the paediatric population to 
unnecessary clinical or other trials’.9 
 
In theory, the European  Directive and the UK’s 2004 Regulations 
only apply to research that involves clinical trials of investigational 
medicinal products,10  with the common law applies to other types 
of research. However, all research involving human participants 
falling within the remit of NHS research ethics committees (RECs) 
must be subjected to ethical scrutiny and receive the appropriate 
approvals before it can commence. This is significant for three 
reasons. First, the National Research Ethics Service (NRES), 
which oversees the operation of all NHS RECs, has adopted a 
policy that requires the standards contained in the UK’s 2004 
Regulations to be applied to all research, even non-clinical trials 
research.11 Secondly, with regard to consent and authorisation for 
a child’s participation in research, this implies that RECs must 
follow the approach specified within those Regulations rather than 
the common law, which has serious implications for the autonomy 
of minors. ,Finally, because some aspects of those Regulations 
are at odds with established ethical guidance, the policy has the 
potential to cause confusion and misapprehensions in the research 
community and amongst members of RECs. 
 
This paper considers the implications of the consent arrangements 
in the UK’s 2004 Regulations for minors who would be regarded as 
competent to give their own consent to medical treatment under 
the common law. By comparing the consent provisions in the 
Regulations with those prevalent in ethical guidelines and the 
common law, it will demonstrate inconsistencies which are likely to 
have a detrimental impact on the autonomy of children involved in 
medical research. Alongside this, I also explore the legal and 
ethical status of the practice of obtaining a child’s assent to 
participate in research and reveal worrying discrepancies between 
the law and ethics in this area. 
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Consent to children’s participation in research – the law and 
ethics 
(i) Statutory authority 
Respect for autonomy demands that consent should be obtained 
prior to conducting any research involving any human participants, 
regardless of whether they are adults or children. Consent also 
provides legal authorisation for any physical contact or the use of 
any data involved in the research process. Consent must be given 
by a person who has the capacity and authority to do so. To this 
end the law operates under the rebuttable presumption that adults 
have capacity to make their own decisions about treatment, 
research, or other aspects of social life, but that minors do not. ref 
Where medical interventions involving children are concerned 
consent is ordinarily given by an adult who has parental 
responsibility (PR) for the child until such time as a minor achieves 
maturity. Usually this means that the parents,12 some other person 
with PR or, occasionally, the courts will consent to the intervention 
until the child is old enough to decide for herself. 
 
However, the age at which a person acquires legal decision-
making capacity and can consent on her own behalf is rather 
imprecise. The Family Law Reform Act 1969 defines the age of 
majority in England and Wales as 18, 13  but with regard to 
beneficial medical treatment, section 8 permits 16 and 17 year olds 
to consent on their own behalf. In Scotland the Age of Legal 
Capacity (Scotland) Act 1991 sets the age at which one attains full 
decision-making capacity at 16 years. But the UK’s  2004 
Regulations define an “adult” as ‘a person who has attained the 
age of 16 years’,14 whereas the 2006 EU Regulations state that 
‘“paediatric population” means that part of the population aged 
between birth and eighteen years’.15 Neither makes any provision 
for consent from competent minors. 
 
(ii) Common law 
In Gillick v West Norfolk and Wisbech Area Health Authority it was 
acknowledged that socially, as in nature, growing up is a 
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continuous process and that ‘the law must be sensitive to human 
development and social change’.16 Accordingly, a minor under the 
age of 16 who has attained sufficient maturity may, in appropriate 
circumstances, lawfully consent to medical treatment on her own 
behalf. But Gillick concerns medical treatment and diagnosis that 
is regarded as in the best interests of the child, rather than 
research andThere are no  specific cases  pertaining to the validity 
of consent from competent minors in relation to research. 
 
(iii) Ethical guidance 
In the context of healthcare research, the vast majority of national 
and international ethical guidance favours an approach that 
maximises the autonomy of all potential research participants, 
including children. To this end, it has long been advised that, 
wherever possible, researchers should request and obtain the 
agreement of children being recruited into research studies.17 The 
Medical Research Council has adopted a more forthright stance 
arguing that ‘where children have sufficient understanding and 
intelligence to understand what is proposed, it is their consent and 
not that of their parent/guardian that is required by law’.18 But he 
legal probity of this is now questionable, in view of the recent 
legislative changes noted above. The General Medical Council 
(GMC) is  more reticent with regard to the status of children’s 
consent and is closer to reflecting the legal position. It thus advises 
that where children are below the age of 18, even if they are ‘able 
to consent for themselves’ the doctor ‘should still consider 
involving their parents, depending on the nature of the research’.19   
 
(iv) International ethical guidance 
The foundations of most domestic and professional ethical 
guidance on human participant research were laid down in the 
Declaration of Helsinki, first published in 1964 and subsequently 
revised, most recently in 2008. Its principles are at the centre of 
the EU Directive and the UK’s 2004 Regulations. It is notable, 
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however, that the latterpurport to incorporate the provisions 
contained in the Declaration of Helsinki as amended in 1996, 
rather than the more recent revisions.20 That version  stipulates 
that when a ‘minor child is in fact able to give consent, the minor’s 
consent must be obtained in addition to the consent of the minor’s 
legal guardian’.21 The most recent version of the Declaration does 
not distinguish minors from others who are unable to consent for 
themselves, but it does insist that ‘no competent individual may be 
enrolled in a research study unless he or she freely agrees’, (para. 
22). This version of the Declaration also offers no guidance on 
what constitutes competence but, in relation to the ethical review 
of research proposals, insists that consideration must be had for 
the ‘laws and regulations of the country … in which the research is 
to be performed’ (para. 15).  This introduces some ambiguity with 
regard to competent minors in the UK because these individuals 
may consent to medical treatment under Gillick, but are not 
recognised under the UK’s 2004 Regulations. Given that earlier 
versions of the Declaration, including the one enshrined in the 
UK’s 2004 Regulations, required consent to be given by competent 
minors, it would not seem unreasonable to assume that, ethically, 
minors who are demonstrably capable of deciding for themselves 
ought properly to fall within the auspices of paragraph 22 of the 
2008 revision. However, this ethical imperative is absent from the 
UK’s 2004 Regulations, and the approach adopted therein has 
important implications for the autonomy of competent minors in 
relation to healthcare research.  
 
Legal standards and ethical best practice – the UK’s 2004 
Regulations 
Under Schedule 1 Part 4 paragraph 13 of the UK’s 2004 
Regulations, ‘the informed consent of the parents or legal 
representative’ must be obtained to authorise the participation of a 
minor in a clinical trial.22 Where very young children are involved 
this is clearly appropriate and is in line with the law on consent to 
the medical treatment of children. It is, however, at odds with most 
of the ethical guidance pertaining to the involvement of children in 
research, and with the common law relating to the right of Gillick 
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Alongside the authorisation of parental proxy consent the UK’s 
2004 Regulations stipulate that the ‘informed consent given by a 
person with parental responsibility or a legal representative to a 
minor taking part in a clinical trial shall represent the minor’s 
presumed will’.23 So, not only is there no provision for the child to 
decide for herself, even if competent to do so, but there seems to 
be an in-built assumption of agreement between parent and child. 
This is disrespectful of the competent minor’s autonomy to deny 
them the opportunity, if not the right, to participate in the decision-
making process, but it is also unrealistic to assume that every 
minor is accepting of and compliant with the views of their parent 
or representative. For these reasons, ethical best practice, as 
enshrined in the majority of guidelines from professional bodies 
and research councils,24 advise that even if a child cannot give a 
legally valid and binding consent, their assent should be obtained 
before they are enrolled into a research study. 
The European Clinical Trials Directive itself is silent on the issue of 
children’s assent, although its significance was recognised and 
defined ‘in the context of Article 4(c) of the Clinical Trials Directive’, 
as, ‘the expression of the minor’s will to participate in a clinical 
trial’.25 Obtaining the assent of those who lack the legal capacity to 
give a valid consent is an important acknowledgment of their 
individual autonomy and self-determination. As such it is pivotal to 
the ethical conduct of research. Yet not only do the UK’s 2004 
Regulationsfail to incorporate any mechanism for the competent 
minor to give consent, they are also silent on the issue of assent.   
 
Schedule 1, Part 4 paragraph 6 of the UK’s 2004 Regulations does 
include the requirement that the minor will be furnished with 
information about the trial and its risks and benefits, ‘according to 
his capacity of understanding, from staff with experience with 
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minors’: a provision which could be regarded as a recognition of 
the autonomy of the minor research participant. However, in the 
context of the Regulations it appears to be aimed more at ensuring 
that research is conducted by properly trained and experienced 
staff, rather than at enhancing the autonomy of child participants. 
That said, under the next paragraph in the Regulations one of the 
conditions and principles which must be satisfied before research 
involving minors can be conducted is that: 
  
The explicit wish of a minor who is capable of forming an 
opinion and assessing the information … to refuse 
participation in, or to be withdrawn from, the clinical trial at any 
time is considered by the investigator.26 
  
Although this is to be read in conjunction with the fact that the 
minor has been given information about the trial and its 
implications, and could be read as promoting the participant’s 
autonomy, it actually falls short. The absence of any requirement 
to do more than merely consider a minor’s explicit wish to be 
withdrawn, or indeed not to participate at all, clearly fails to respect 
the minor’s autonomy. It is also out of step with most ethical 
guidance. For example, the GMC advises that children ‘should not 
usually be involved in research if they object or appear to object in 
either words or actions, even if their parents consent’, 27  which 
represents a clear acknowledgement of the significance that ought 
to be placed on the child’s views in these circumstances. A similar 
precept appears in the influential guidance published by the 
Council for International Organisations of Medical Sciences 
(CIOMS), which insists that ‘a child’s refusal to participate in the 
research will be respected’.28 Ethically then, active dissention from 
a child who refuses to participate in the research, or wishes to be 
withdrawn from it, should be acted upon, and not merely 
‘considered’. The failure of the  UK’s 2004 Regulations to reflect 
such provisions is detrimental to children’s rights to autonomy, 
especially in the case of competent minors. 
 
In a healthcare environment where individual autonomy is widely 
championed one might expect that gaining the agreement of 
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Comment [f1]: Is this right? 
competent minors to their participation in research would be 
regarded as a crucial aspect of the regulatory regime. This is 
particularly so because a central principle of the UK’s 2004 
Regulations is the requirement that, “the clinical trial has been 
designed to minimise pain, discomfort, fear and any other 
foreseeable risk in relation to the disease and the minor’s stage of 
development.”29 Aside from the appeal to autonomy, involving the 
minor in the consent process would seem an obvious way to 
minimise, fear and emotional, if not physical, discomfort. But, 
instead, the parent or person with PR is given absolute power and 
complete authority to represent the ‘presumed will’ of the child 
regardless of the age or experience of the minor.   
 
Conclusions 
There are thus a number of tensions between the law and ethical 
guidance in relation to research involving competent minors. The 
latter suggests, indeed requires, that children should be included in 
any decision about whether to participate in research, but the legal 
regulation of research makes no provision for their consent or 
assent to be obtained. This tension is exacerbated by the fact that 
NRES policy requires NHS RECs to treat all research they review 
according to the standards in the UK’s 2004 Regulations, even that 
which does not involve pharmaceutical products or medical 
devices. As a consequence, the autonomy of competent minors 
may be severely compromised, and inconsistency and confusion is 
likely to be caused in the process of ethical review. More 
specifically, RECs may opt to adhere to the UK’s 2004 Regulations 
in relation to clinical trials research but, contrary to NRES 
guidelines, decide to follow ethical and professional guidance 
otherwise. The result will be a double standard whereby the level 
of respect for the autonomy of competent minors becomes 
dependent on the kind of research they participate in. This position 
is unethical and also out of step with practices in other, 
comparable, jurisdictions, such as the US where it is expected that 
researchers will at least seek assent from children above the age 
of seven.30 Denying children the opportunity, if not the right, to 
participate in the decision about whether to be involved in research 
is overly paternalistic, particularly with regard to competent minors. 
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As Sarah Elliston has argued, the ethical approach that maximises 
child and adolescent autonomy is far preferable, and where a 
competent minor wishes to make the decision she ‘should be at 
liberty to do so’.31 There are now so many safeguards to protect 
the interests of research participants that, so long as the research 
is scientifically sound and has ethical approval, a competent minor 
who is capable of understanding the implications of their 
participation should be permitted to give their own informed 
consent, and that consent ought to be authoritative. Some 
commentators go one step further arguing that where a minor is 
competent to give consent, not only should she be trusted to make 
self-interested decisions, but should also be permitted to act 
altruistically for the benefit of others.32 Moreover, where the minor 
is not capable of providing a legal consent, parental consent 
should be obtained, and deemed legally valid only where the 
child’s assent is forthcoming.  
 
Yet the UK’s 2004 Regulations do not require consent or assent 
from minors, and this offends all ethical guidelines pertaining to 
children and research. It is also counter to the central premise of 
research ethics which dictates that no competent person should be 
expected to participate in research without first giving their 
voluntary, informed consent. Whilst it is understandable to seek to 
avoid exploitation of a population as vulnerable as children, it must 
be recognised that competent minors are just that; competent and 
capable of making their own informed decisions. The present 
position means that the autonomy of competent minors 
participating in healthcare research is better protected by non-
enforceable ethical guidelines than it is by the law. In a research 
arena dominated by individual autonomy and self-determination 
that is most certainly not okay. 
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